PARIS ARIANAS: Open Payments
NPI 1467551002 · BRENTWOOD, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$776 in 24 payments from 7 companies in 2025. Trend: 2023 $100 · 2024 $252 · 2025 $776
Food & beverage: $776
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 11 | $451 |
| E.R. Squibb & Sons, L.L.C. | 3 | $87 |
| Otsuka America Pharmaceutical, Inc. | 3 | $64 |
| Teva Pharmaceuticals USA, Inc. | 3 | $64 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $54 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
Products named: INGREZZA, COBENFY, CAPLYTA, REXULTI, AUSTEDO XR, UZEDY, Auvelity, FANAPT.
Industry payments across NY — which companies pay providers there.
